Targeting the CD47-SIRPA Axis in Oncology: A Competitive Assessment of Technologies, Dual Targeting, Biomarkers, Combination Therapies & More
Targeting the CD47-SIRPα axis is emerging as one of the most promising new cancer immunotherapy approaches seeking to target innate immune response. This report reveals intense global interest and a growing list of stakeholders operating in this field. Users of this report get an un-biased, fact driven analysis of the position of each molecule and commercial player, always kept up to date with twice weekly updates.
Most of the identified molecules in this report are either anti-CD47 antibodies or SIRPα-Fc recombinant proteins. In healthy cells, CD47 serves as a ""don’t eat me"" signal by binding to the transmembrane SIRPα protein on phagocytic cells, preventing the engulfment of ""self"" by macrophages. In several cancer types, tumor cells overexpress CD47 to elude the immune system. Exploration of this property has been the driving force to attract hundreds of million of dollars in investments to companies like Tioma Therapeutics, Surface Oncology and Forty Seven, the latter of which has just recently completed a $113 million IPO of its common stock on June 26th, 2018. Deals in this area include the early adopter move in 2012 by Celgene securing Inhibrx’ anti-CD47 antibody in a $500 million dollar deal to the recent billion dollar plus agreement between OSE Immunotherapeutics and Boehringer Ingelheim.
On the clinical development front, this report identifies fewer than ten molecules targeting the CD47-SIRPα axis which have made it into the clinic and so far with encouraging results. Several of these trials also shed light on biomarker- and combination therapies of interest. On the horizon, this field will soon have another injection of candidate therapies with bispecific CD47 antibodies entering the clinic in late 2018 or early 2019.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook